Market Risers: 3i Group plc, 4d Pharma PLC, Accrol Group Holdings PLC, AstraZeneca plc

Accrol Group Holdings plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The share price for 3i Group plc EPIC code: LON:III has gained 2.51% or 21.6 points during the course of today’s session so far. Traders are a positive bunch while the stock has been in play. The period high was 883.4 and hitting a low of 857.8. The total volume of shares exchanged so far has reached 835,521 with the average number of shares traded daily being 2,157,764. The stock 52 week high is 975 about 113.6 points difference from the previous days close and putting the 52 week low at 694 is a variance of 167.4 points. 3i Group plc has a 20 SMA of 923.01 and a 50 day simple moving average now of 928.66. Market capitalisation is now £8,590.64m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for 3i Group plc being recorded at Monday, March 26, 2018 at 1:11:01 PM GMT with the stock price trading at 883 GBX.

 

 

The stock price for 4d Pharma PLC found using EPIC: LON:DDDD has increased 4.6% or 5.45 points throughout the session so far. Buyers have stayed positive during the trading session. The high for the period has reached 123.95 while the low for the session was 115. The number of shares traded by this point in time totalled 5,260 with the daily average number around 62,670. The 52 week high for the share price is 530 around 411.5 points in difference on the previous days close and a 52 week low being 115 which is a variance of 3.5 points. This puts the market capitalisation now at £80.16m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for 4d Pharma PLC being recorded at Monday, March 26, 2018 at 12:05:17 PM GMT with the stock price trading at 123.95 GBX.

 

 

The trading price for Accrol Group Holdings PLC with ticker code: LON:ACRL has increased 9.17% or 0.63 points during today’s session so far. Market buyers seem confident throughout the trading session. Range high for the period so far is 7.5 meanwhile the session low reached 6.7. The number of shares traded by this point in time totalled 1,878,512 while the daily average number of shares exchanged is 1,262,327. A 52 week share price high is 166.01 which comes in at 159.14 points difference from the previous days close and putting the 52 week low at 0.42 a difference of some 6.45 points. This puts the market cap at £7.23m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Accrol Group Holdings PLC being recorded at Monday, March 26, 2018 at 1:09:51 PM GMT with the stock price trading at 7.5 GBX.

 

 

The stock price for AstraZeneca plc ticker code: LON:AZN has moved up 1.3% or 62.3 points throughout today’s trading session so far. Buyers seem confident while the stock has been in play. The high for the period has peaked at 4850.3 and hitting a low of 4788.08. The number of shares traded by this point in time totalled 520,050 while the average shares exchanged is 2,255,189. The stock 52 week high is 5520 which is 732 points difference from the previous days close and putting the 52 week low at 4260 making a difference of 528 points. AstraZeneca plc now has a 20 SMA at 4833.43 and also a 50 day SMA of 4904.52. This puts the market cap at £61,426.54m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Monday, March 26, 2018 at 1:11:04 PM GMT with the stock price trading at 4850.3 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

Search

Search